Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $177.00
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 3, 26 | HC Wainwright & Co. |
Daily · Wilder smoothing
| maintain |
| Buy |
| Buy |
| May 4, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Feb 24, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 22, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 4, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 28, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Feb 24, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 4, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 31, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 69.87 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 84.19 | Oscillator | Sell |
| Williams %R (14) | -3.38 | Oscillator | Sell |
| MACD (12, 26, 9) | 1.19 (Hist 0.96) | Oscillator | Strong Buy |
| Average Directional Index (14) | 20.35 (+DI 31.7 / -DI 11.4) | Trend | Buy |
| EMA 20 | 170.29 | MA | Strong Buy |
| SMA 20 | 168.90 | MA | Strong Buy |
| EMA 50 | 169.85 | MA | Strong Buy |
| SMA 50 | 171.12 | MA | Strong Buy |
| SMA 200 | 169.03 | MA | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 16, 26 | Gonzalez Ren Anthony | officer: SVP and Chief R&D Officer | 0 | — | |
| Sep 16, 26 | Gonzalez Ren Anthony | officer: SVP and Chief R&D Officer | 0 | — | |
| Feb 8, 27 | Gonzalez Ren Anthony | officer: SVP and Chief R&D Officer | 240 @ $143.43 | $34.42K | |
| Apr 1, 26 | Gilson Erin Leigh | officer: Chief Accounting Officer | 0 | — | |
| Apr 1, 26 | Gilson Erin Leigh | officer: Chief Accounting Officer | 0 | — | |
| Feb 10, 23 | Gilson Erin Leigh | officer: Chief Accounting Officer | 600 @ $138.07 | $82.84K | |
| Feb 8, 24 | Gilson Erin Leigh | officer: Chief Accounting Officer | 600 @ $138.09 | $82.85K | |
| Feb 8, 25 | Gilson Erin Leigh | officer: Chief Accounting Officer | 600 @ $143.43 | $86.06K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Balchem posted strong sales growth of 8.6% during the quarter and free cash flow of $57.9 million. BCPC's business is great—growing earnings, low borrowings, and continuous share buybacks. My DCF valuation states the stock should be priced at roughly $88. The current price of $177 reflects an overvaluation of roughly 50%.
Third-quarter net sales rose 8.6% year over year to $291 million. Human nutrition and health segment sales increased 8.1% to $188 million.
Balchem Corporation (BCPC) Q3 2026 Earnings Call Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 23, 2026 | 1.43 | 1.57 | Beat 9.8% | $290.7M |
| Jul 31, 2026 | 1.27 | 1.40 | Beat 10.2% | $284.0M |
| Apr 30, 2026 | 1.33 | 1.25 | Miss -6.0% | $270.7M |
| Feb 20, 2026 | 1.29 | 1.31 | Beat 1.6% | $263.6M |
| Oct 21, 2025 | 1.36 | 1.35 | Miss -0.7% | $267.6M |
| Jul 31, 2025 | 1.25 | 1.27 | Beat 1.6% | $255.5M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Oct 23, 2026 | 2026-10-23 16:18:30 | View |
| 8-K | Oct 23, 2026 | 2026-10-23 07:21:05 | View |
| 3 | Sep 24, 2026 | 2026-09-24 16:23:46 | View |
| 10-Q | Jul 31, 2026 | 2026-07-31 16:20:15 | View |
| 8-K | Jul 31, 2026 | 2026-07-31 07:32:28 | View |
| 8-K | Jul 27, 2026 | 2026-07-24 21:52:36 | View |
| 8-K | Jun 22, 2026 | 2026-06-22 16:34:55 | View |
| 11-K | Jun 18, 2026 | 2026-06-18 16:35:47 | View |
| 10-Q | Apr 30, 2026 | 2026-04-30 16:33:55 | View |
| 8-K | Apr 30, 2026 | 2026-04-30 07:34:58 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BCPC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 33.1x | 42.1x · sector 16.6x | Elevated |
| Forward P/E (FY26E) | 32.8x | EPS est. 5.40 | In line |
| Price / Book | 4.3x | 4.7x | In line |
| Price / Sales | 5.1x | 5.3x | In line |
| EV / EBITDA | 20.4x | 24.0x | In line |
| Return on equity | 13.2% | — | Healthy |
| Gross margin | 36.5% | 32.8% | In line |
| Debt / Equity | 0.03 | 0.25 | Conservative |
| Piotroski / Altman Z | 8/9 | Z 11.27 | Safe zone |
Discounted cash flow model